Gil Roth09.07.11
SGS plans to expand the offerings in its Poitiers, France facility by adding cell-based bioassays. The move includes investment in the latest generation of flow cytometers and a Biosafety Level 2 (BL-2) suite. SGS has also hired a senior study director with cell-based assay experience in the fields of apoptosis, necrosis, proliferation, oxidative stress, lysosomes, mitochondrial perturbation and extracellular/intracellular factors. The company plans on further recruitment in the next six months to meet customer demand.
"SGS is making this investment to meet the growing need for these services," said Alain Renoux, general manager for the Life Science Services facility in Poitiers. He noted that SGS is currently transferring two cell-based assays from a "Top Pharma client," and that the new investment complements the 5,400-sq.-ft. expansion that began in October 2010 to increase biological assay capacity. The lab is one of SGS' two GLP-compliant bioanalytical labs in Europe.
"SGS is making this investment to meet the growing need for these services," said Alain Renoux, general manager for the Life Science Services facility in Poitiers. He noted that SGS is currently transferring two cell-based assays from a "Top Pharma client," and that the new investment complements the 5,400-sq.-ft. expansion that began in October 2010 to increase biological assay capacity. The lab is one of SGS' two GLP-compliant bioanalytical labs in Europe.